Mark Miller

Academic title(s):

Adjunct member, Department of Microbiology and Immunology
Affiliate member, Department of Medicine, JGH

Contact Information

Address:

Jewish General Hospital
#G200, 3755 Cote-Ste-Catherine Rd.
Montreal, Quebec, H3T 1E2

Email address:

mark.miller2 [at] mcgill.ca

Division:

Adjunct Members

Location:

Lady Davis Institute, Jewish General Hospital

Graduate supervision:

NOT ACCEPTING STUDENTS

Selected publications:

Louie TG, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. NEJM
2011;364:422-31Louie TG, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. NEJM 2011;364:422-31

Forgetta V, Oughton MT, Marquis P, et al (including Miller M). A fourteen genome comparison of identifies DNA markers for severe disease-associated strains of Clostridium difficile. J Clin Micro 2011;49(6):2230-8

Mullane KM, Miller MA, Weiss K et al. Efficacy of Fidaxomicin versus Vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. CID 2011; 53(5): 440-447

Miller M, Blanchette R, Spigaglia P, et al. Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of Rifampin Etest for Rifamycin resistance.J Clin Micro 2011:4310-21

Cornely OA, Miller MA, Louie TJ, et al. Treatment of First Recurrence of Clostridium difficile infection: Fidaxomicin versus Vancomycin. CID 2012;55(S2):S154-61

Sears P, Crook DW, Louie TJ, Miller MA, Weiss K.Fidaxomicin attains high fecal concentrations following oral administration in patients with Clostridium difficile infection. CID 2012;55(S2):S116-20

Back to top